论文部分内容阅读
目的观察抗肿瘤药长春瑞滨联合顺铂治疗晚期乳腺癌的疗效。方法符合入组条件的晚期乳腺癌42例,长春瑞滨(NVB)25mg/m2,第1￣8天联合顺铂(DDP)30mg/m2,第1￣3天,化疗3周期。结果RR24例(57.1%),CR2例(4.8%),PR22例(52.3%)。主要毒副作用为骨髓抑制、胃肠道反应。白细胞减少的发生率95.2%,其中Ⅲ￣Ⅳ度者7.1%。恶心、呕吐的发生率92.9%,无Ⅲ￣Ⅳ度者。结论长春瑞滨联合顺铂方案是一个既有效毒性又相对小的选择。
Objective To observe the efficacy of anti-tumor drug vinorelbine plus cisplatin in the treatment of advanced breast cancer. Methods Forty-two patients with advanced breast cancer who met the inclusion criteria were treated with 25 mg / m2 vinorelbine (NVB), 30 mg / m2 DDP on day 1 to day 8, and 3 cycles of chemotherapy for 1 to 3 days. Results RR24 cases (57.1%), CR2 cases (4.8%), PR22 cases (52.3%). The main side effects of bone marrow suppression, gastrointestinal reactions. The incidence of leukopenia 95.2%, of which Ⅲ ~ Ⅳ degrees were 7.1%. Nausea, vomiting, the incidence of 92.9%, no Ⅲ ~ Ⅳ degrees. Conclusions Vinorelbine plus cisplatin is an effective and relatively toxic alternative.